Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. , it was in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.
via PubMed
{{Chembox | Verifiedfields = changed | verifiedrevid = 486401721 | ImageFile = Abexinostat.svg | ImageClass = skin-invert-image | ImageSize = | IUPACName = 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide | OtherNames = PCI-24781; CRA-024781 | Section1 = | Section2 = | Section3 = | Section5 = }}
Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. , it was in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).